On the other hand, studies have demonstrated that IL-33 signaling via AREG represents a dominant pathway for gut-associated group 2 innate lymphoid cells, whose activation promotes protection against colitis and colitis-associated cancer (43). This evidence concerns the gene IL33 and colitis.